Ipragliflozin
- Generic Name
- Ipragliflozin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21FO5S
- CAS Number
- 761423-87-4
- Unique Ingredient Identifier
- 3N2N8OOR7X
- Background
Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03118713
- Locations
- 🇰🇷
Site 11, Guri-si, Korea, Republic of
🇰🇷Site 01, Seoul, Korea, Republic of
🇰🇷Site 09, Seoul, Korea, Republic of
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT03076112
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 175
- Registration Number
- NCT02897219
- Locations
- 🇯🇵
Site JP00005, Aichi, Japan
🇯🇵Site JP00022, Fukuoka, Japan
🇯🇵Site JP00006, Hiroshima, Japan
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 44
- Registration Number
- NCT02875821
- Locations
- 🇰🇷
Yonsei University College of Medicine, Department of internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul, Korea, Republic of
Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 103
- Registration Number
- NCT02847091
- Locations
- 🇯🇵
Site JP00008, Hiroshima, Japan
🇯🇵Site JP00002, Tochigi, Japan
🇯🇵Site JP00004, Osaka, Japan
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT02577003
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 141
- Registration Number
- NCT02577016
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 77
- Registration Number
- NCT02564211
Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 11412
- Registration Number
- NCT02479399
Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 100
- Registration Number
- NCT02291874
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath